Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2391 • ACR Convergence 2024
Identification of Patients with ANA Negative and Double Stranded DNA Positive: What Is the Significance in Daily Rheumatology Practise
Güllü Sandal Uzun¹, Emily Apsley² and David Isenberg², ¹University College London, London, England, United Kingdom, ²University College London, London, United Kingdom
Background/Purpose: The anti-nuclear antibody (ANA test) is a sensitive screening tool used when assessing patients with possible autoimmune rheumatic diseases (ARD). Homogeneous staining positivity is…
Abstract Number: 2410 • ACR Convergence 2024
A Novel Treatment Response Measure for SLE Clinical Trials (TRM-SLE): Selection of Domains and Candidate Measures
Kathryn Connelly¹, Rachel Koelmeyer¹, Darshini Ayton¹, Lavanya Rajagopala², Ambika Wahklu², John May³, Raychel Barallon⁴, Rangi Kandane-Rathnayake⁵, Laura Eades¹, kate Gregory¹ and Eric Morand⁶, and the TRM-SLE Taskforce, ¹Monash University, Melbourne, Victoria, Australia, ²Monash Health, Melbourne, Victoria, Australia, ³Monash Medical Centre, Richmond, Victoria, Australia, ⁴Monash Health, Clayton, Victoria, Australia, ⁵Monash University, Clayton, Victoria, Australia, ⁶School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: The success of randomised controlled trials (RCTs) in SLE has been hampered by limitations of current outcome measures, contributing to negative or discordant trial…
Abstract Number: 2426 • ACR Convergence 2024
Multi-OMICs Analysis Including Lipidomics to Correlate Baseline OMICs Profiles with Disease Activity and Response to Different Immunomodulatory Treatments in Patients with Systemic Lupus Erythematosus – An Exploratory Pilot Study Using a Multi-OMICs Approach
Michaela Koehm¹, Samuel Rischke², Robert Gurke³, Gerd Geißlinger⁴ and Frank Behrens¹, ¹University Hospital Goethe University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ²Goethe University Frankfurt, Institute of Clinical Pharmacology, Frankfurt, Germany, ³Goethe University Frankfurt, Institute of Clinical Pharmacology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, ⁴Goethe University Frankfurt, Institute of Clinical Pharmacology and Fraunhofer Insitute for Translational Medicine and Pharmacology ITMP, Frankfurt
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a very heterogeneous clinical presentation and severity. Despite the variety of treatment options available,…
Abstract Number: 2547 • ACR Convergence 2024
Neurophysiological Phenotypes Are Uncoupled from Toll-like Receptor-Mediated Peripheral Disease in a Mouse Model of Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Cecilia Stumpf¹, Vanessa Rodriguez¹ and Carla Cuda², ¹Northwestern University, Chicago, ²Northwestern University, Chicago, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse clinical presentations, including neuropsychiatric symptoms (NPSLE). Despite being a major cause of morbidity…
Abstract Number: 2622 • ACR Convergence 2024
Quality of Care for Childhood-Onset Lupus Nephritis: Suboptimal Completion of Disease Activity Monitoring
Emily Smitherman¹, Justin Leach¹, Aimee Hersh², Melissa Mannion¹, Jinoos Yazdany³ and Jeffrey Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Utah, Salt Lake City, UT, ³UCSF, San Francisco, CA, ⁴University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Poorly controlled childhood-onset lupus nephritis (cLN) can lead to end-stage kidney disease (ESKD), requiring kidney replacement therapies with substantial financial and quality of life…
Abstract Number: 0094 • ACR Convergence 2024
Small GTPase Rab4A Regulates Mouse Behavior Through Altered Serum Serotonin Levels and Microglial mTORC1 Activation in Lupus-prone B6.TC Mice
Thomas Winans¹, Xiaojing Wang², Joshua Lewis², Jessica Nolan¹, Laurence Morel³ and Andras Perl⁴, ¹SUNY Upstate Medical University, Syracuse, ²SUNY Upstate Medical University, Syracuse, NY, ³University of Texas health San Antonio, San Antonio, TX, ⁴SUNY, Syracuse, NY
Background/Purpose: Rab4A is a small GTPase that is overexpressed in patients and mice with systemic lupus erythematosus (SLE, PubMed ID: 23897774; PubMed ID 31805010). Rab4A…
Abstract Number: 0169 • ACR Convergence 2024
Impact of Sense of Control Among People Living with SLE
Amanda Eudy¹, S. Sam Lim², Charmayne M. Dunlop-Thomas³, Jinoos Yazdany⁴, Patti Katz⁵ and Laura Plantinga⁶, ¹Duke University, Raleigh, NC, ²Emory University, Atlanta, GA, ³Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ⁴University of California San Francisco, San Francisco, CA, ⁵UCSF, San Rafael, CA, ⁶University of California, San Francisco, San Francisco, CA
Background/Purpose: SLE is a disease characterized by cycles of remitting and relapsing symptoms that can be unpredictable, stressful, and cause an individual to feel they…
Abstract Number: 0194 • ACR Convergence 2024
Machine Learning Methods to Predict Cardiovascular Risk in Hispanic Patients with Systemic Lupus Erythematosus
Ariana Gonzalez-Melendez¹, Jeann Hernandez-Franco², Dylan Cedres-Rivera³ and Abiel Roche-Lima³, ¹University of Puerto Rico - Medical Science Campus, Guaynabo, PR, ²University of Puerto Rico, San Juan, PR, Puerto Rico, ³Center for Collaborative Research in Health Disparities, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, San Juan, PR, Puerto Rico
Background/Purpose: The most common cause of death among patients with systemic lupus erythematosus (SLE) is cardiovascular disease (CVD). Previous studies have performed cardiovascular risk stratification;…
Abstract Number: 0362 • ACR Convergence 2024
Development of a Theory-based Digital Messaging Program to Reduce Fatigue in Systemic Lupus Erythematosus
Anna Deck¹, Paula Caras², Kiran Singh³, Monique Gore-Massy⁴, Faye Chiu⁵, Sara Folta⁶ and Shanthini Kasturi³, ¹Tufts University School of Medicine, Portland, ME, ²Tufts University School of Medicine, Boston, MA, ³Tufts Medical Center, Boston, MA, ⁴Lupus Foundation of America, New Jersey, ⁵N/A, New York City, NY, ⁶Tufts University/Tufts University Friedman School of Nutrition, Boston, MA
Background/Purpose: Fatigue is the single most prevalent symptom of systemic lupus erythematous (SLE), affecting 80-90% of patients, and is often refractory to pharmacologic therapy. Non-pharmacologic…
Abstract Number: 0448 • ACR Convergence 2024
A Pregnant Lupus Patient’s Journey: Single-Center Outcomes and Opportunities
Divya Singh¹, Maya Faison², Molly Leavitt³, Megan Clowse⁴ and Cuoghi Edens⁵, ¹University of Chicago, Chicago, IL, ²University of Chicago, Chapel Hill, NC, ³MacNeal Hospital/Loyola Medicine, Chicago, IL, ⁴Duke University, Chapel Hill, NC, ⁵Section of Pediatric Rheumatology, Section of Rheumatology, University of Chicago, Chicago, IL
Background/Purpose: Nearly half of systemic lupus erythematosus (SLE) patients will experience pregnancy complications. These complications include increased rates of prematurity, miscarriage, pre-eclampsia, and mortality. Maternal…
Abstract Number: 0620 • ACR Convergence 2024
Clinical Efficacy and Patient-Reported Outcomes in Anti-Ro/Sjögren’s Syndrome–Related Antigen a Antibody–Positive Patients with Active SLE Treated WithDeucravacitinib in the Phase 2 PAISLEY Trial
Benjamin A. Fisher¹, Hendrika Bootsma², Vibeke Strand³, Wan-Fai Ng⁴, Thomas Wegman⁵, Brandon Becker⁶, Jiyoon Choi⁶, Antoine Sreih⁶, Leo Chen⁷, Antonia Christodoulou⁶ and Eric Morand⁸, ¹University of Birmingham, Birmingham, United Kingdom, ²Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, ³Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁴Institute of Cellular Medicine, Newcastle University, Gateshead, United Kingdom, ⁵Bristol Myers Squibb, Beaver Falls, PA, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Richmond, BC, Canada, ⁸School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of adults with moderate to…
Abstract Number: 0641 • ACR Convergence 2024
Predictive Validity of Coronary Artery Calcium Scoring in Low Risk Systemic Lupus Erythematous Patients
Katherine Chakrabarti¹, Apurba Chakrabarti², Emily Lewis² and William McCune³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Hospital, Ann Arbor, MI, ³U Michigan, Ann Arbor, MI
Background/Purpose: Traditionally, a coronary artery calcium (CAC) score of zero is associated with low rates (0.1-0.2% annualized risk) of major adverse cardiovascular outcomes (MACE). While…
Abstract Number: 0657 • ACR Convergence 2024
Data-driven Bayesian Network Analysis for Predicting Difficult-to-treat (DTT) Lupus Nephritis
Jagan K L¹, Augustine Jose², Vishnupriya G¹, Dellan S¹, Dhanush S¹, Samskruthi Reddy Tokala¹, Bhavana Mashetty¹, Chengappa Kavadichanda³, Sachith ganapathy¹, Aishwarya Gopal⁴, Rithik Roshan¹, Sareddy Sai vignesh Reddy¹, Sonal Mehra⁵, Molly Thabah¹ and Vir Singh Negi⁶, ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ²Jawaharlal Institute of Postgraduate Medical Education and Research, Gorimedu, Puducherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁴Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, ⁵JAYPEE HOSPITAL, Noida, Uttar Pradesh, India, ⁶AIIMS, Bilaspur, Puducherry, Puducherry, India
Background/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE), with 14-33% failing to respond to standard treatments. This study assesses treatment…
Abstract Number: 0676 • ACR Convergence 2024
Understanding the Patient Burden of Lupus: Insights from Multi-Faceted Ethnography Research
Jeanette Andersen¹, Ina Meyer², Neeta Camadoo³, Tracy Machado⁴, Shreya Saraf⁴ and Mohamed Akrout², ¹Lupus Europe, Brussels, Belgium, ²F. Hoffmann-La Roche Ltd, Basel, ³Roche Products Ltd, Welwyn Garden City, ⁴Elma Research International, London
Background/Purpose: Systemic lupus erythematosus (SLE or lupus) is a chronic autoimmune disease that affects multiple organs, including the skin, joints, lungs, heart, kidneys and brain.…
Abstract Number: L02 • ACR Convergence 2023
Mutational Analysis of UNC93B1 Identifies Regulatory Regions Mutated in Human SLE
John Huizar¹, Victoria Rael², Julian Yano², Leianna Slayden³, Madeleine Weiss⁴, Robert Saxton⁴, Bo Liu⁵, Olivia Majer⁶ and Gregory Barton⁷, ¹UCSF, San Francisco, CA, ²Division of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, UC Berkeley, Berkeley, CA, ³HHMI at UC Berkeley, Berkeley, CA, ⁴UC Berkeley, Berkeley, CA, ⁵Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shangai, China, ⁶Max Planck Institute for Infection Biology, Berlin, Germany, ⁷UC Berkeley / HHMI, Berkeley, CA
Background/Purpose: Endosomal nucleic acid-sensing toll-like receptors 3, 7 and 9 are key innate immune sensors of dsRNA, ssRNA and ssDNA, respectively, whose activities must be…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].